Sign up Australia
Proactive Investors - Run By Investors For Investors

OBJ Limited to reveal licensing details

The halt will remain in place until Monday 24th April 2017.
OBJ Limited to reveal licensing details
The company is focused on drug delivery technology

OBJ Limited (ASX:OBJ) has been granted a trading halt by the ASX, pending details in relation to the licensing of a second technology.

The halt will remain in place until the opening of trade on Monday 24th April 2017, or earlier if an announcement is made to the market.

View full OBJ profile View Profile

OBJ Limited Timeline

January 25 2016
December 02 2014

Related Articles

May 31 2017
Written responses from America’s Food & Drug Administration and the Medicines & Healthcare products Regulatory Agency (MHRA) here in Britain support its timeline, which sees marketing approval for the product in the second-quarter of 2019.
January 25 2017
Analyst Vadim Alexandre, of the company’s broker Northland Capital, said Wednesday’s update provided “better visibility” on the trial timetable.
Concept of a DNA strand
May 30 2017
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making advances altering the inner workings of the human body to tackle deadly diseases

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use